http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Elghanam, Doaa M (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
FHIT Gene Expression in Acute Lymphoblastic Leukemia and its Clinical Significance
Malak, Camelia A Abdel,Elghanam, Doaa M,Elbossaty, Walaa Fikry Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.18
Background: To investigate the expression of the fragile histidine triad (FHIT) gene in acute lymphoblastic leukemia and its clinical significance. Materials and Methods: The level of expressed FHIT mRNA in peripheral blood from 50 patients with acute lymphoblastic leukemia (ALL) and in 50 peripheral blood samples from healthy volunteers was measured via RT-PCR. Correlation analyses between FHIT gene expression and clinical characteristics (gender, age, white blood count, immunophenotype of acute lymphoblastic leukemia and percentage of blast cells) of the patients were performed. Results: The FHIT gene was expressed at $2.49{\pm}7.37$ of ALL patients against $14.4{\pm}17.9$ in the healthy volunteers. The difference in the expression levels between ALL patients and healthy volunteers was statistically significant. The rate of gene expression did not significantly vary with immunophenotype subtypes. Gene expression was also found to be correlated with increase of total leukocyte and decrease in platelets, but not with age, gender, immunophenotyping or percentage of blast cells. Conclusions: FHIT gene expression is low in acute lymphoblastic leukemia and could be a useful marker to monitor minimal residual disease. This gene is also a candidate target for the immunotherapy of acute lymphoblastic leukemia.
-
Sublingual Immunotherapy in Allergic Rhinitis: Efficacy, Safety, Adherence and Guidelines
Omar Ali Aboshady,Karim Mohamed Elghanam 대한이비인후과학회 2014 Clinical and Experimental Otorhinolaryngology Vol.7 No.4
Allergic rhinitis (AR) is a globally increasing health problem affecting the quality of life. Specific immunotherapy is an available causal treatment changing the basic allergic mechanisms of the disease. Over one hundred years, subcutaneous immunotherapy (SCIT) was developed and proved its efficacy but many adverse effects were recorded including anaphy- laxis. In 1986, sublingual immunotherapy (SLIT) was introduced as an alternative solution to solve this problem. Our study aims to discuss SLIT from the points of efficacy, safety, adherence and guidelines developed. A literature search was con- ducted in Medline/PubMed and the Cochrane Library in January 2013 using the keywords “allergic rhinitis, sublingual im- munotherapy, efficacy, safety, compliance, adherence, guidelines.” All types of publications were included. We augmented our study by searching the reference lists of identified reviews. SLIT has been established in many guidelines as an evi- dence-based effective treatment in AR with safer profile than SCIT. The meta-analyses confirmed its efficacy and showed a significant reduction in both symptoms and medication scores. The most common recorded adverse effects were minor lo- cal effects in the mouth, gastrointestinal reactions with few cases of anaphylaxis and no fatality. Adherence is more favor- able for SLIT mainly because it is safe, noninvasive and easily taken at home. We support the call to conduct large multi- centric studies to gain more statistical power and overcome the problem of heterogeneity observed in the meta-analyses.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
